Pyxis Oncology

Yahoo Finance • 4 days ago

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, M... Full story

Yahoo Finance • 12 days ago

Emera Reaches Analyst Target Price

In recent trading, shares of Emera Inc (Symbol: EMA) have crossed above the average analyst 12-month target price of $47.85, changing hands for $47.96/share. When a stock reaches the target an analyst has set, the analyst logically has tw... Full story

Yahoo Finance • 13 days ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported today that Pyxis On... Full story

Yahoo Finance • last month

September 2025's Promising Penny Stock Opportunities

As the U.S. stock market experiences fluctuations, with major indices like the Dow Jones and S&P 500 recently hitting record highs before turning lower, investors are closely monitoring economic indicators such as job reports and potential... Full story

Yahoo Finance • 2 months ago

Pyxis Oncology to Participate in September Investor and Industry Conferences

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., Pr... Full story

Yahoo Finance • 2 months ago

Pyxis Oncology GAAP EPS of -$0.30 beats by $0.05, revenue of $2.8M

* Pyxis Oncology press release [https://seekingalpha.com/pr/20201906-pyxis-oncology-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:PYXS [https://seekingalpha.com/symbol/PYXS]): Q2 GAAP EPS of -$0.30 b... Full story

Yahoo Finance • 3 months ago

Pyxis Oncology announces retirement of CFO and COO Pamela Connealy

Pyxis Oncology , Inc. (NASDAQ:PYXS) reported the retirement of Pamela Connealy from her roles as Chief Financial Officer and Chief Operating Officer, effective Tuesday. According to a statement based on a filing with the Securities and Exc... Full story

Yahoo Finance • 4 months ago

Pyxis Oncology shareholders elect three directors at annual meeting

Pyxis Oncology , Inc. (NASDAQ:PYXS), a Boston-based pharmaceutical company currently trading at $1.14 per share, announced the voting results from its Annual Meeting of Stockholders held Wednesday in a virtual format. The company’s stock h... Full story

Yahoo Finance • 5 months ago

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Ch... Full story

Yahoo Finance • 6 months ago

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chie... Full story

Yahoo Finance • 7 months ago

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and metastatic head and nec... Full story

Yahoo Finance • 8 months ago

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (F... Full story

Yahoo Finance • 8 months ago

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

- Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® (pembrolizumab) in multiple solid tumors - Phase 1 monotherapy trial expanded to include coh... Full story

Yahoo Finance • 2 years ago

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Ken Kobay... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of NAPCO Security Technologies Inc. (NASDAQ: PYXS)

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of NAPCO Security Technologies Inc. (NASDAQ: PYXS) concerning possible breaches of fiduciary duty. To obtain additional informa... Full story

Yahoo Finance • 2 years ago

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 (a fully human immu... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of fiduciary duty. To obtain additional information, go to... Full story

Yahoo Finance • 2 years ago

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced four abstracts for four dif... Full story

Yahoo Finance • 2 years ago

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced its participation in two upc... Full story

Yahoo Finance • 2 years ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation with clinically and commercially validat... Full story